Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
Paolo Bonfanti(University of California San Diego), Lucia Taramasso(Ospedale Policlinico San Martino), Roberto Gulminetti(University of Pavia), Paolo Maggi(Università degli Studi di Enna Kore), Giancarlo Orofino(Ospedale Amedeo di Savoia), Francesca Vichi, Giuseppe Vittorio De Socio(University of Perugia), Antonio Di Biagio, Elena Ricci(Mario Negri Institute for Pharmacological Research), Canio Martinelli(Azienda Ospedaliero-Universitaria Careggi), Paola Tatarelli(Ospedale "Santa Maria delle Croci" di Ravenna), Barbara Menzaghi(Ospedale di Circolo di Busto Arsizio), Giordano Madeddu(University of Sassari), Nicola Squillace(Azienda Ospedaliera San Gerardo)
Cited by 63
Related Papers
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels
|medRxiv|2020|234
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
|Clinical Infectious Diseases|2012|208